Eli Lilly just delivered the result the obesity field has been waiting two years for. On May 21, 2026, the company announced topline data from TRIUMPH-1, the pivotal Phase 3 trial testing retatrutide in adults with obesity who do not have diabetes. Participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks, and those who continued into a two-year extension reached an average of 30.3%. Nearly half of the high-dose group lost 30% or more, a level of weight loss that until now has been associated mainly with bariatric surgery.
This is a different trial from the two retatrutide readouts we have already covered. It is separate from TRIUMPH-4, which tested retatrutide in obesity patients who also had knee osteoarthritis, and from TRANSCEND-T2D-1, the first Phase 3 diabetes trial. TRIUMPH-1 is the big one: the flagship obesity study that anchors retatrutide's eventual case for FDA approval. Here is the full data and what it means.
What's New: TRIUMPH-1 at a Glance
TRIUMPH-1 is the largest and most important retatrutide trial reported so far. It enrolled adults with obesity, or overweight plus at least one weight-related health problem, and specifically excluded people with diabetes so the results reflect weight loss on its own.
| Parameter | Detail |
|---|---|
| Trial name | TRIUMPH-1 |
| Phase | Phase 3 |
| Duration | 80 weeks (with a 104-week extension) |
| Participants | 2,339 adults |
| Population | Obesity, or overweight with a weight-related condition, without diabetes |
| Design | Randomized, double-blind, placebo-controlled |
| Dose arms | 4 mg, 9 mg, 12 mg (once weekly) vs. placebo, split evenly |
| Dose escalation | Stepped up every 4 weeks to the target dose |
| Primary endpoint | Percent change in body weight |
| Announced | May 21, 2026 |
The trial size matters. At 2,339 participants, TRIUMPH-1 is large enough to give regulators a clear read on both how well the drug works and how well people tolerate it. Splitting participants evenly across three doses also tells doctors something practical: how much weight loss to expect at a lower, gentler dose versus the maximum.
The Headline: Up to 30% Weight Loss
Retatrutide produced weight loss that climbed steadily with dose, and the placebo group barely moved. These are the 80-week results.
| Dose | Weight Loss (%) | Weight Loss (lbs) |
|---|---|---|
| 4 mg | -19.0% | -47.2 lbs |
| 9 mg | -25.9% | -64.4 lbs |
| 12 mg | -28.3% | -70.3 lbs |
| Placebo | -2.2% | -5.5 lbs |
A few things stand out.
Even the lowest dose was strong. The 4 mg arm lost 19.0%, which is roughly in line with what the best currently approved obesity drugs achieve at their highest doses. In other words, retatrutide's entry-level dose is competitive with another drug's ceiling.
The dose response is clean. Weight loss rose with every step up in dose, from 19.0% to 25.9% to 28.3%. That kind of orderly pattern gives doctors a reliable dial: a patient who cannot tolerate the top dose still has a strong lower option.
The placebo result confirms the effect is real. Placebo participants lost just 2.2%. The gap between drug and placebo, more than 26 percentage points at the top dose, is large and unambiguous.
The 30% Milestone: Surgery-Level Results Without Surgery
The single most striking number in TRIUMPH-1 is not the average. It is how many people crossed the 30% weight loss line, a threshold long considered the territory of weight-loss surgery rather than medication.
| Dose | Participants Losing 30% or More |
|---|---|
| 4 mg | 15.3% |
| 9 mg | 37.9% |
| 12 mg | 45.3% |
| Placebo | 0.5% |
On the 12 mg dose, 45.3% of participants lost at least 30% of their body weight. For comparison, gastric bypass and sleeve gastrectomy typically produce total weight loss in the 25% to 35% range. A weekly injection putting nearly half of patients into that band is a genuine shift in what medicine can offer people with obesity.
Two Years In: The 104-Week Extension
A subset of participants with more severe obesity, a body mass index of 35 or higher, continued treatment in an extension that ran to 104 weeks, or two full years. Their results were the best in the trial.
- 532 participants with a starting BMI of 35 or higher continued to the two-year mark.
- On 12 mg, average weight loss reached 30.3%, about 85.0 lbs.
- 65.3% of that group dropped below the obesity threshold entirely, moving out of the BMI 30-or-higher category.
Two findings deserve attention. First, weight loss kept building past the 80-week mark rather than flattening out, which suggests the full effect of the drug takes longer than the usual trial window to appear. Second, moving roughly two out of three people with significant obesity out of the obese BMI range is the kind of outcome that changes long-term health risk, not just the number on the scale.
Safety and Tolerability
Retatrutide's side-effect profile looked like the rest of its drug class. The most common problems were gastrointestinal and tended to show up during the dose-escalation period.
- Nausea: 28.6% to 42.4% across the dose arms
- Diarrhea: 25.2% to 34.1%
- Constipation: 23.8% to 26.1%
- Discontinuation due to side effects: 4.1% to 11.3%, compared with 4.9% on placebo
The pattern is familiar from semaglutide and tirzepatide: mostly stomach-related effects, usually manageable with slow dose increases. Notably, even at the top dose the share of people who quit because of side effects stayed in the low double digits, which is reassuring for a drug producing this much weight loss.
How It Compares
Cross-trial comparisons are not head-to-head and should be read with care, since trial lengths and patient groups differ. Still, the gap is wide enough to be meaningful.
| Drug | Trial | Top-Dose Weight Loss |
|---|---|---|
| Retatrutide | TRIUMPH-1 (80 wks) | -28.3% (-30.3% at 104 wks) |
| Tirzepatide | SURMOUNT-1 (72 wks) | about -21% to -22.5% |
| Semaglutide | STEP-1 (68 wks) | about -15% |
Retatrutide is the first obesity drug to push average weight loss toward the 30% mark in a large Phase 3 trial. Tirzepatide redefined expectations at roughly 21%, and semaglutide did so before it at about 15%. Retatrutide now sits a clear step above both.
Why a Triple Agonist Goes Further
The reason retatrutide reaches higher than the drugs before it comes down to how many targets it hits. Semaglutide acts on one hormone receptor. Tirzepatide acts on two. Retatrutide acts on three:
- GLP-1: reduces appetite and slows how fast the stomach empties, so people feel full sooner and longer.
- GIP: helps the body handle fat and sugar more efficiently and may ease the nausea that comes with appetite suppression.
- Glucagon: raises energy expenditure, meaning the body burns more calories at rest.
That third target, glucagon, is the key difference. The first two mainly reduce how much you eat. Glucagon adds an increase in how much you burn. Combining both sides of the energy equation is the leading explanation for why retatrutide's numbers run higher than the dual and single agonists.
What's Next
TRIUMPH-1 is the first of several pivotal trials, and Lilly has said more readouts are coming this year.
- TRIUMPH-2 is testing retatrutide in adults who have both obesity and type 2 diabetes.
- TRIUMPH-3 is testing it in adults with obesity and established cardiovascular disease, the trial that could show whether the weight loss translates into fewer heart attacks and strokes.
Together with the diabetes and osteoarthritis data already reported, these trials build the package Lilly will use to seek FDA approval. A regulatory filing would follow the completion of the core program rather than a single trial, so retatrutide is not yet available as an approved medicine.
What This Means
For anyone following the weight-loss field, TRIUMPH-1 confirms that retatrutide is the most powerful obesity drug to reach late-stage trials so far. It does not change its current status: retatrutide remains an investigational drug, not approved by the FDA, and it is not the same thing as a compounded or research-grade peptide sold outside the regulated supply chain.
It is also worth keeping the distinction between trials clear. The 30% figure comes from a controlled, two-year study with medical supervision, careful dose escalation, and a specific patient population. Results outside that setting will not automatically match it.
For the deeper background on how retatrutide works, its place among the GLP-1 drugs, and typical research dosing, see our full retatrutide profile and our overview of peptides for weight loss.
Bottom Line
Retatrutide's pivotal obesity trial delivered up to 28.3% weight loss at 80 weeks and 30.3% at two years, with nearly half of high-dose patients reaching surgery-level results. Its three-receptor design appears to be the reason it outperforms tirzepatide and semaglutide. The next readouts, in diabetes and heart disease, will decide how broad its eventual approval could be.
